Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New developments in thrombosis therapy.

M Diaz-Ricart1

  • 1Hospital Clinic, IDIBAPS, Barcelona, Spain.

Drug News & Perspectives
|August 26, 2003
PubMed
Summary
This summary is machine-generated.

The 16th International Congress on Thrombosis highlighted new uses for low-molecular-weight heparins and discussed tissue factor's role in thrombosis treatment. Updates on developmental anticoagulants were also presented, advancing thrombosis research.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A freeze-dried platelet-derived hemostatic agent improves hemostasis in patients with severe thrombocytopenia before and after standard platelet transfusion: Studies ex vivo in the total thrombus-formation analysis system 01.

Transfusion·2026
Same author

Role of fibrinogen concentrates for treatment of critical perioperative hemorrhage.

Drugs of today (Barcelona, Spain : 1998)·2021
Same author

Diagnostic challenges in von Willebrand disease. Report of two cases with emphasis on multimeric and molecular analysis.

Platelets·2020
Same author

Emicizumab for routine prophylaxis to prevent bleeding episodes in patients with hemophilia A.

Drugs of today (Barcelona, Spain : 1998)·2018
Same author

Betrixaban: a direct oral inhibitor of activated factor X for the prophylaxis of venous thromboembolism in patients hospitalized for acute medical illness.

Drugs of today (Barcelona, Spain : 1998)·2017
Same author

Andexanet alfa: a recombinant mimetic of human factor Xa for the reversal of anticoagulant therapies.

Drugs of today (Barcelona, Spain : 1998)·2017
Same journal

New drug discovery and development in India.

Drug news & perspectives·2013
Same journal

Are we living in the end of the blockbuster drug era?

Drug news & perspectives·2010
Same journal

Molecule of the Month. TAK-875.

Drug news & perspectives·2010
Same journal

Epigenetic alterations of tumor marker microRNAs: towards new cancer therapies.

Drug news & perspectives·2010
Same journal

Electroporation: a promising method for the nonviral delivery of DNA vaccines in humans?

Drug news & perspectives·2010
Same journal

Trioxaquines: hybrid molecules for the treatment of malaria.

Drug news & perspectives·2010
See all related articles

Area of Science:

  • Cardiovascular Medicine
  • Hematology

Background:

  • The 16th International Congress on Thrombosis convened to discuss advancements in managing thrombotic conditions.
  • Thrombosis remains a significant clinical challenge, necessitating continuous research into novel therapeutic strategies.

Purpose of the Study:

  • To review the latest developments in thrombosis treatment.
  • To highlight new indications for low-molecular-weight heparins and update on relevant clinical trials.
  • To discuss the roles of key hemostatic factors and emerging anticoagulant therapies.

Main Methods:

  • Presentations and symposia at the International Congress on Thrombosis.
  • Review of recent clinical trial data on anticoagulants.
  • Discussion of the pathophysiology involving tissue factor and its inhibitors.

Related Experiment Videos

Main Results:

  • New indications for low-molecular-weight heparins were explored.
  • Updates on ongoing and completed clinical trials were provided.
  • The significance of tissue factor and tissue factor pathway inhibitor in thrombosis was extensively reviewed.

Conclusions:

  • The congress underscored the evolving landscape of thrombosis treatment.
  • Low-molecular-weight heparins continue to demonstrate expanding therapeutic roles.
  • Developmental anticoagulants show promise for future clinical application in managing thrombosis.